Actinium Pharmaceuticals Inc. – NYSE: ATNM
Actinium Pharmaceuticals gained over 30% in today’s trading on exceptionally heavy volumes. ATNM, traded on the NYSE, has an average daily volume of 275k, but today over 5.5 million shares traded hands.
New York, NY-based Actinium Pharmaceuticals is a biotech company that develops innovative targeted payload immunotherapies for the treatment of advanced cancers. The Company’s radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target.
Actinium’s lead product is Iomab-B and is in its crucial Phase 3 clinical trial. Iomab-B is a myeloablative therapy, designed to destroy a patient’s bone marrow so that a patient can receive bone marrow from a donor via a transplant. Also in Actiniumn’s pipeline is its Alpha Particle Immunotherapy (APIT) platform. Being 100 times more powerful than beta particles, alpha therapy is effective in cancers that are not sensitive to beta irradiation such as victims of Acute Myeloid Leukemia (AML). AML treatment utilizing APIT has demonstrated extremely high cancer cell kill levels.
On January 27 – 28, 2017, in Dallas, TX, Chief Medical Officer, Dr. Mark Berger will present at the 3rd Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dava Oncology is sponsoring the event as part of their Oncology Meeting Innovations program. Dr. Berger’s talk will focus on Actinium’s Iomab-B.
ATNM shares took a 20% dive in September when the company announced a public offering of an additional 8 million shares at $1.25 a piece plus offering the underwriters a 30-day option on an additional 15% of the sold stock. The price gapped down to below $1.40 and broke the $1 barrier in late October. Shares rebounded slightly and traded around the $1 handle until today when the stock took off and closed at $1.36 – just two cents short of the daily high.
Actinium Pharmaceuticals has yet to post any sales but institutions own over 10% of its shares – a fact which comforts some investors. ATNM had its largest earnings loss in 2012 when the company announced a loss of $7.58 per share. Earnings have never been positive; the last three years have seen per share losses under $1 with 2015 posting a loss of $0.55. Two firms follow Actinium Pharmaceuticals and both rate ATNM shares as a “Strong Buy”.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 3:59 PM EST||$ 1.36|
|Market Cap (mlns)||$ 57.42|
|Shares Outstanding (mlns)||55.75|
|Share Float (mlns)||51.06|
|Short Interest Ratio||4.3|